State of the art surgical management of ovarian cancer

Cancer Research Therapy and Control

Volumn 9, Issue 3-4, 1999, Pages 373-382

  Hoskins, William J ^a   Chi, Dennis S ^a   Boente, Matthew P ^b   Rubin, Stephen C ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ovarian cancer; Surgery

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MELPHALAN;

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

EID: 0032881773     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Abu-Rustum N.R., Barakat R.R., Siegel P.L., Venkatraman E., Curtin J.P., and Hoskins W.J. (1996). Second-look operation for epithelial ovarian cancer: Laparoscopy or laparotomy? Obstet Gynecol, 88: 549-553.
2. Blythe J.G., Wahl T.P. (1982). Debulking surgery: Does it increase the quality of survival? Gynecol Oncol, 14: 396-408.
3. Bristow R.E., Montz F.J., and Lagasse L.D. (1998). Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Proc Annu Meet SGO, 24.
4. Brown C.L., Lewis J.L. (1993). Palliative surgery in ovarian cancer. In: Markman M, Hoskins, W.J. (eds). Cancer of the Ovary. (New York, Raven Press), pp. 217-226.
5. Castaldo T.W.. Petrilli E.S., Ballon S.C.. and Lagasse L.D. (1989). Intestinal operations in patients with ovarian cancer. Oncology, 3: 25-36.
6. Chi D.S., Fong Y, Venkatraman E.S., and Barakat R.R. 1997). Hepatic resection for metastatic gynecologic carcinomas Gynecol Oncol, 66: 45-51.
7. Clarke-Pearson D.L., Chin N., DeLong E.R., Rice R., and Creasman W.T. (1987). Surgical management of intestinal obstruction in ovarian cancer. Gynecol Oncol, 26: 11-18.
8. Conte P.P., Bruzzone M., Chiara S., Sertoli M.R., Daga M.G., Rubagotti A., Conio A., Rivolo M., Rosso R., and Santi L.(1986). A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol, 4: 965971.
9. Curtin JP, Malik R, Venkatraman ES, Barakat RR, and Hoskins WJ (1997). Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol, 64(1): 9-12.
10. DelgadoG., Oram D.H., and Petrilli E.S. (1984). Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol, 18: 293-298.
11. DeVita V.T. (1993). Principles of chemotherapy. In DeVita V.T., Hellman S., Rosenberg S.A (eds): Cancer: Principles and Practice of Oncology (ed 4). (Philadelphia, Lippincott), pp. 276-292.
12. Ehrlich C.E.. Einhorn L., Williams S.D., and Morgan J. (1979). Chemotherapy for stage III-IV epithelial ovarian cancer with cisdichlorodiammineplatinum (II), adriamycin and cyclophosphamide: A preliminary report. Cancer Treat Rep, 63: 281288.
13. Gaducci A., Satori E., Tiziano M.. Zola P., Landoni F., Fanucchi A.. Palai N., Alessi C., Ferrero A.M., Cosio S., and Cristofani R. (1998). Analysis of failures after negative second look in patients with advanced ovarian cancer: An Italian multicenter study. Gynecol Oncol, 68 (2): 150-155.
14. Goldie J.H., Coldman J.A.. (1979). A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 63: 1727-1733.
15. Griffiths C.T. (1986). Surgery at the time of diagnosis in ovarian cancer. In Blackledge G., Chan K.K. (eds); Management of Ovarian Cancer (London. Butterworth and Co.) pp. 6-75.
16. Griffiths C.T. (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr, 42: 101-104.
17. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. (1983). Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol, 61: 413-420.
18. Hoskins W.J., Bundy B.N., Thigpen J.T., and OmuraG.A. (1992). The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ova-rian cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 47: 159-166.
19. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Herman M, Ball H., and Berek J.S. (1994). The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol, 170: 974-980.
20. Hoskins W.J., Rubin S.C. (1991). Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol, 18: 213221.
21. Hoskins W.J. (1993). Primary cytoreduction, in Markman M, Hoskins WJ (eds): Cancer of the Ovary. (New York, NY, Raven), pp. 163-173,
22. Hoskins W.J, Rubin S.C., Dulaney E., Chapman D., Almadrones L., Saigo P., Markman M., Hakes T., Reichman B., and Jones W.B. (1989). Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol, 34: 365-71.
23. Krebs H.B., Goplerud D.R. (1983). Surgical management of bowel obstruction in advanced ovarian carcinoma. Gynecol Oncol, 61: 327-330.
24. Landis S.H., Murray T., Bolden S., and Wingo P.A. ( 1998). Cancer Statistics, 1998. CA Cancer J Clin, 48: 6-29.
25. Larson J.E., Podczaski E.S., Manetta A., Whitney C.W., and Mortel R. (1989). Bowel obstruction in patients with ovarian carcinoma: Analysis of prognostic factors. Gynecol Oncol, 55: 6165.
26. Lawton EG., Redman C.W.E., Luesley D.M., Chan K.K., and BlackledgeG. (1989). Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol, 73: 61-65.
27. Lippman S.M., Alberts D.S., and Slymen D.J. (1988). Second-look laparotomy in epithelial ovarian carcinoma. Cancer, 61: 25712577.
28. Liu P.C., Benjamin I., Morgan M.A., lung S.A., Mikukta J.J., and Rubin S.C. (1997). Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol, 64: 4.
29. Lund B., Hansen M., Lundvall F., Nielsen N.C., Sorenson B.I., and Hansen H.H. (1989). Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstet, 169, 213-218.
30. Morris M., Gershenson D.M., and Wharton J.T. (1989). Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first-line therapy. Gynecol Oncol, 33: 1-5.
31. Munkharah A.R., Hallum III A.V., Morris M., Burke T.W., Levenback C., Atkinson E.N., Wharton J.T., and Gershenson D.M. (1997). Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol, 64: 13-17.
32. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E., van Oosterom A.T., Willemse P.H., Heintz A.P., van Lent M., Trimbos J.B., Bouma J., and Vermerken J.B. (1987). Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs. CP) in advanced ovarian carcinoma. J Clin Oncol, 5: 1157-1168.
33. Ng L.W., Rubin S.C., Hoskins W.J., Jones W.B., Hakes T.B., Markman M., Reichman B., Almadrones L., and Lewis J.L. Jr. (1990). Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 38: 358-363.
34. Omura G.A., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., and Homesley H.D. (1986). A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: A Gynecologic Oncology Group study. Cancer, 57: 1725-1730.
35. Ozols R.F., Rubin S.C., Thomas G., and Robboy S. (1997). Epithelial ovarian cancer. In Hoskins W.J., Ferez C.A., Young R.C. (eds): Principles and Practice of Gynecologic Oncology (ed 2) (Philadelphia, Lippincott-Raven), pp. 919-986.
36. Piver M.S., Barlow J.J., Lele S.B., and Frank A. (1982). Survival after ovarian cancer induced intestinal obstruction. Gynecol Oncol; 13: 44-49.
37. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Emrich L.J. (1988). The impact of aggressive debulking surgery and cisplatin based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6: 983-989.
38. Pohl R., Dallenbach-Hallweg G., Plugge T., and Czernobilsky B. (1984). Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaecol Oncol, 3: 160-169.
39. Redman J.R., Petroni G.R.. Saigo P.E., Geller N.L., and Hakes T.B. (1986). Prognostic factors in advanced ovarian cancer. J Clin Oncol, 4:515-523.
40. Rubin S.C., Hoskins W.J., Benjamin 1., and Lewis J.L. Jr. (1989). Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol, 34: 16-19.
41. Rubin S.C., Hoskins W.J. (1993). Primary surgery for ovarian carcinoma. In Sciarra J.J., Droegemueller W. (eds) Gynecology and Obstetrics. (Philadelphia, Lippincott), pp. 1-11.
42. Rubin S.C., Lewis J.J. (1988). Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol, 8: 75-91.
43. Tunca J.C., Buchler D.A., Mack E.A., Ruzicka F.F., Crowley J.J, and Carr WF (1981). The management of ovarian cancer caused bowel obstruction. Gynecol Oncol, 12: 186-192.
44. Vaccarello L., Rubin S.C., Vlamis V., Wong G., Jones W.B., Lewis, J.L. Jr., and Hoskins W.J. (1995). Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol, 57: 61.
45. van der Burg M.E.L., van Lent M., Buyse M., Kobierska A., Columbo N., Favalli G., Lacave A.J., Nardi M., Renard J., and Pecorelli S. (1995). The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med, 332: 629-634.
46. Vogl S.E,. Pasano M., Kaplan B.H., Greenwald E., Arsenau J., and Bennett B. (1983). Cisplatin based combination chemotherapy for advanced ovarian cancer: High overall response rate with curative potential only in women with small tumor burdens. Cancer, 5/: 2024-2030.
47. Wharton J.T., Herson J. (1981). Surgery for common epithelial tumors of the ovary. Cancer 48: 582-589.
48. Young R.C., Chabner B.A., Hubbard S.P. Fisher R.I., Bender R.A., Anderson T., Simon R.M., Canellos O.P., and De Vita V.T. Jr. (1978). Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299, 1261-1266.